Emerging Bladder Cancer Biomarkers and Targets of Therapy

George J Netto; Laura J Tafe

doi:10.1016/j.ucl.2015.08.006

Emerging Bladder Cancer Biomarkers and Targets of Therapy

Urol Clin North Am. 2016 Feb;43(1):63-76. doi: 10.1016/j.ucl.2015.08.006.

Authors

George J Netto¹, Laura J Tafe²

Affiliations

¹ Department of Pathology, The Johns Hopkins Medical Institutes, Baltimore, MD, USA; Department of Oncology, The Johns Hopkins Medical Institutes, Baltimore, MD, USA; Department of Urology, The Johns Hopkins Medical Institutes, Baltimore, MD, USA. Electronic address: gnetto1@jhmi.edu.
² Department of Pathology, Dartmouth-Hitchcock Medical Center, One Medical Center Drive, Lebanon, NH 03756, USA; Geisel School of Medicine at Dartmouth, 1 Rope Ferry Rd, Hanover, NH 03755, USA.

PMID: 26614029
DOI: 10.1016/j.ucl.2015.08.006

Abstract

Bladder cancer is a heterogeneous disease characterized by complex networks of molecular alterations and gene expression. This review summarizes some of the recent genomic studies that have further advanced the understanding of the pathways driving bladder cancer, highlighting several important biomarkers and potential targeted therapeutic strategies that are now in clinical trials. In addition, noninvasive techniques to evaluate biomarkers in patients' urine and serum for early detection and surveillance are discussed.

Keywords: Biomarkers; Bladder cancer; Clinical trials; Genomics; Targeted therapy; Urothelial carcinoma.

Publication types

Review

MeSH terms

Biomarkers, Tumor / blood
Biomarkers, Tumor / genetics*
Biomarkers, Tumor / urine
Disease Progression
Genomics*
Humans
Prognosis
Urinary Bladder Neoplasms / diagnosis*
Urinary Bladder Neoplasms / genetics
Urinary Bladder Neoplasms / therapy

Substances

Biomarkers, Tumor